BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 23349392)

  • 1. VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease.
    Eikenboom J; Federici AB; Dirven RJ; Castaman G; Rodeghiero F; Budde U; Schneppenheim R; Batlle J; Canciani MT; Goudemand J; Peake I; Goodeve A;
    Blood; 2013 Mar; 121(12):2336-9. PubMed ID: 23349392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS-IPS study.
    Pagliari MT; Rosendaal FR; Ahmadinejad M; Badiee Z; Baghaipour MR; Baronciani L; Benítez Hidalgo O; Bodó I; Budde U; Castaman G; Eshghi P; Goudemand J; Karimi M; Keikhaei B; Lassila R; Leebeek FWG; Lopez Fernandez MF; Mannucci PM; Marino R; Oldenburg J; Peake I; Santoro C; Schneppenheim R; Tiede A; Toogeh G; Tosetto A; Trossaert M; Yadegari H; Zetterberg EMK; Peyvandi F; Federici AB; Eikenboom J
    J Thromb Haemost; 2022 May; 20(5):1106-1114. PubMed ID: 35092343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease.
    Sanders YV; Groeneveld D; Meijer K; Fijnvandraat K; Cnossen MH; van der Bom JG; Coppens M; de Meris J; Laros-van Gorkom BA; Mauser-Bunschoten EP; Leebeek FW; Eikenboom J;
    Blood; 2015 May; 125(19):3006-13. PubMed ID: 25673639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD).
    Haberichter SL; Castaman G; Budde U; Peake I; Goodeve A; Rodeghiero F; Federici AB; Batlle J; Meyer D; Mazurier C; Goudemand J; Eikenboom J; Schneppenheim R; Ingerslev J; Vorlova Z; Habart D; Holmberg L; Lethagen S; Pasi J; Hill FG; Montgomery RR
    Blood; 2008 May; 111(10):4979-85. PubMed ID: 18344424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic determinants of enhanced von Willebrand factor clearance from plasma.
    Seidizadeh O; Baronciani L; Pagliari MT; Cozzi G; Colpani P; Cairo A; Siboni SM; Biguzzi E; Peyvandi F
    J Thromb Haemost; 2023 May; 21(5):1112-1122. PubMed ID: 36754679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Utility of von Willebrand Factor Propeptide in the Differential Diagnosis of von Willebrand Disease and Acquired von Willebrand Syndrome.
    Stufano F; Boscarino M; Bucciarelli P; Baronciani L; Maino A; Cozzi G; Peyvandi F
    Semin Thromb Hemost; 2019 Feb; 45(1):36-42. PubMed ID: 29913537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expanded phenotype-genotype correlations in a pediatric population with type 1 von Willebrand disease.
    Robertson JD; Yenson PR; Rand ML; Blanchette VS; Carcao MD; Notley C; Lillicrap D; James PD
    J Thromb Haemost; 2011 Sep; 9(9):1752-60. PubMed ID: 21711445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival.
    Haberichter SL; Balistreri M; Christopherson P; Morateck P; Gavazova S; Bellissimo DB; Manco-Johnson MJ; Gill JC; Montgomery RR
    Blood; 2006 Nov; 108(10):3344-51. PubMed ID: 16835381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Von Willebrand factor propeptide makes it easy to identify the shorter Von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease.
    Sztukowska M; Gallinaro L; Cattini MG; Pontara E; Sartorello F; Daidone V; Padrini R; Pagnan A; Casonato A
    Br J Haematol; 2008 Oct; 143(1):107-14. PubMed ID: 18691167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. von Willebrand factor propeptide to antigen ratio identifies platelet activation and reduced von Willebrand factor survival phenotype in mice.
    Jacobi PM; Kanaji S; Jakab D; Gehrand AL; Johnsen JM; Haberichter SL
    J Thromb Haemost; 2018 Mar; 16(3):546-554. PubMed ID: 29285851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factor VIII pharmacokinetics associates with genetic modifiers of VWF and FVIII clearance in an adult hemophilia A population.
    Ogiwara K; Swystun LL; Paine AS; Kepa S; Choi SJ; Rejtö J; Hopman W; Pabinger I; Lillicrap D
    J Thromb Haemost; 2021 Mar; 19(3):654-663. PubMed ID: 33219619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. von Willebrand factor: evidence for variable clearance in vivo according to Y/C1584 phenotype and ABO blood group.
    Davies JA; Collins PW; Hathaway LS; Bowen DJ
    J Thromb Haemost; 2008 Jan; 6(1):97-103. PubMed ID: 17949477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Similarity in joint and mucous bleeding syndromes in type 2N von Willebrand disease and severe hemophilia A coexisting with type 1 von Willebrand disease in two Chinese pedigrees.
    Qin HH; Xing ZF; Wang XF; Ding QL; Xi XD; Wang HL
    Blood Cells Mol Dis; 2014 Apr; 52(4):181-5. PubMed ID: 24351655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis of von Willebrand disease type 2N: a simplified method for measurement of factor VIII binding to von Willebrand factor.
    Miller CH; Kelley L; Green D
    Am J Hematol; 1998 Aug; 58(4):311-8. PubMed ID: 9692396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-wide studies of von Willebrand factor propeptide identify loci contributing to variation in propeptide levels and von Willebrand factor clearance.
    Ozel AB; McGee B; Siemieniak D; Jacobi PM; Haberichter SL; Brody LC; Mills JL; Molloy AM; Ginsburg D; Li JZ; Desch KC
    J Thromb Haemost; 2016 Sep; 14(9):1888-98. PubMed ID: 27359253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor VIII levels.
    Hickson N; Hampshire D; Winship P; Goudemand J; Schneppenheim R; Budde U; Castaman G; Rodeghiero F; Federici AB; James P; Peake I; Eikenboom J; Goodeve A;
    J Thromb Haemost; 2010 Sep; 8(9):1986-93. PubMed ID: 20492463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired von Willebrand syndrome: von Willebrand factor propeptide to von Willebrand factor antigen ratio predicts remission status.
    Lee A; Sinclair G; Valentine K; James P; Poon MC
    Blood; 2014 Jul; 124(5):e1-3. PubMed ID: 24951428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FVIII/VWF ratio is not a reliable predictor of VWD in children.
    Branchford BR; Ruegg K; Villalobos-Menuey E; Jacobson LJ; Di Paola JA; Manco-Johnson M
    Pediatr Blood Cancer; 2014 May; 61(5):936-9. PubMed ID: 24281894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.